BRPI0508082A8 - Anticorpo monoclonal de tenascina antihumano - Google Patents

Anticorpo monoclonal de tenascina antihumano

Info

Publication number
BRPI0508082A8
BRPI0508082A8 BRPI0508082A BRPI0508082A BRPI0508082A8 BR PI0508082 A8 BRPI0508082 A8 BR PI0508082A8 BR PI0508082 A BRPI0508082 A BR PI0508082A BR PI0508082 A BRPI0508082 A BR PI0508082A BR PI0508082 A8 BRPI0508082 A8 BR PI0508082A8
Authority
BR
Brazil
Prior art keywords
monoclonal antibody
antihuman
tenascin
tenascin monoclonal
seq
Prior art date
Application number
BRPI0508082A
Other languages
English (en)
Inventor
De Santis Rita
Pelliccia Angela
Palombo Giovanna
Carminati Paolo
Original Assignee
Tecnogen Scpa
Tecnogen Spa
Sigma Tau Ind Farmaceuti
Alfasigma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tecnogen Scpa, Tecnogen Spa, Sigma Tau Ind Farmaceuti, Alfasigma Spa filed Critical Tecnogen Scpa
Publication of BRPI0508082A publication Critical patent/BRPI0508082A/pt
Publication of BRPI0508082A8 publication Critical patent/BRPI0508082A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

ANTICORPO MONOCLONAL DE TENASCINA ANTIHUMANO. Um anticorpo monoclonal de tenascina antihumano é descrito, cujas seqüências de regiões variáveis das cadeias leve e pesada são a SEQ ID NO: 1 e a SEQ ID NO: 2, respectivamente, seus fragmentos proteolíticos capazes de se ligar a um epitopo antigênico dentro da região A(1-4)-D da tenascina humana, seus derivados recombinantes, seus conjugados e seus análogos funcionais similares capazes de se ligar a um epitopo antigênico dentro da região A(1-4)-D da tenascina humana.
BRPI0508082A 2004-02-27 2005-02-16 Anticorpo monoclonal de tenascina antihumano BRPI0508082A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000105A ITRM20040105A1 (it) 2004-02-27 2004-02-27 Anticorpo monoclonale antitenascina umana.
PCT/IT2005/000078 WO2005082938A2 (en) 2004-02-27 2005-02-16 Anti-human tenascin monoclonal antibody

Publications (2)

Publication Number Publication Date
BRPI0508082A BRPI0508082A (pt) 2007-07-17
BRPI0508082A8 true BRPI0508082A8 (pt) 2017-12-26

Family

ID=34897820

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0508082A BRPI0508082A8 (pt) 2004-02-27 2005-02-16 Anticorpo monoclonal de tenascina antihumano

Country Status (16)

Country Link
US (1) US7989171B2 (pt)
EP (1) EP1718678B1 (pt)
JP (1) JP5191036B2 (pt)
KR (1) KR101266389B1 (pt)
CN (1) CN1946740B (pt)
AR (1) AR047819A1 (pt)
AU (1) AU2005217237B2 (pt)
BR (1) BRPI0508082A8 (pt)
CA (1) CA2558718C (pt)
ES (1) ES2654065T3 (pt)
HK (1) HK1100848A1 (pt)
IT (1) ITRM20040105A1 (pt)
MX (1) MXPA06009674A (pt)
PL (1) PL1718678T3 (pt)
PT (1) PT1718678T (pt)
WO (1) WO2005082938A2 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070115947A (ko) 2005-02-11 2007-12-06 아밀린 파마슈티칼스, 인크. 선택가능한 특성들을 가지는 ｇｉｐ 유사체 및 하이브리드폴리펩타이드
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
JP2012031084A (ja) * 2010-07-29 2012-02-16 Tokyo Univ Of Science 抗腫瘍剤
WO2014113459A1 (en) * 2013-01-15 2014-07-24 Duke University Hiv-1 neutralizing factor
WO2014189842A2 (en) * 2013-05-21 2014-11-27 NX Pharmagen Use of tenascin-c as an extracellular marker of tumor-derived microparticles
GB201616596D0 (en) * 2016-09-29 2016-11-16 Nascient Limited Epitope and antibodies
WO2023240135A2 (en) 2022-06-07 2023-12-14 Actinium Pharmaceuticals, Inc. Bifunctional chelators and conjugates

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5634076A (en) * 1994-10-04 1997-05-27 Analog Devices, Inc. DMA controller responsive to transition of a request signal between first state and second state and maintaining of second state for controlling data transfer
US6014709A (en) * 1997-11-05 2000-01-11 Unisys Corporation Message flow protocol for avoiding deadlocks
US6335014B1 (en) * 1998-06-17 2002-01-01 The Institute Of Physical And Chemical Research Medicament for suppressing cancer metastasis
US6521593B1 (en) * 1999-02-01 2003-02-18 Childrens Hospital Los Angeles Methods for inhibiting brain tumor growth
WO2000066628A1 (en) * 1999-05-01 2000-11-09 University Of Medicine And Dentistry Of New Jersey Neurite outgrowth and guidance by tenascin-c
US7058750B1 (en) * 2000-05-10 2006-06-06 Intel Corporation Scalable distributed memory and I/O multiprocessor system
JP3646159B2 (ja) 2001-02-08 2005-05-11 国立大学法人三重大学 抗テネイシンｃモノクローナル抗体及び当該抗体を産生するハイブリドーマ
ITRM20010079A1 (it) * 2001-02-16 2002-08-16 Sigma Tau Ind Farmaceuti Amminoderivati della biotina e loro coniugati con chelanti macrociclici.
CN1317303C (zh) * 2002-02-26 2007-05-23 希格马托制药工业公司 抗人腱生蛋白单克隆抗体
ITRM20020128A1 (it) 2002-03-08 2003-09-08 Sigma Tau Ind Farmaceuti Dimeri di avidina efficaci nell'incrementare la concentrazione di biotina radioattiva nella immunoterapia con "pretargeting".

Also Published As

Publication number Publication date
ITRM20040105A1 (it) 2004-05-27
JP5191036B2 (ja) 2013-04-24
KR101266389B1 (ko) 2013-05-28
AU2005217237B2 (en) 2011-12-22
US7989171B2 (en) 2011-08-02
JP2008506355A (ja) 2008-03-06
AU2005217237A1 (en) 2005-09-09
PL1718678T3 (pl) 2018-05-30
EP1718678B1 (en) 2017-10-11
MXPA06009674A (es) 2007-03-21
CA2558718C (en) 2015-01-13
WO2005082938A2 (en) 2005-09-09
KR20070002029A (ko) 2007-01-04
EP1718678A2 (en) 2006-11-08
PT1718678T (pt) 2017-12-29
US20100297003A1 (en) 2010-11-25
BRPI0508082A (pt) 2007-07-17
CN1946740A (zh) 2007-04-11
CN1946740B (zh) 2012-09-05
WO2005082938A3 (en) 2005-12-15
AR047819A1 (es) 2006-02-22
HK1100848A1 (en) 2007-09-28
ES2654065T3 (es) 2018-02-12
CA2558718A1 (en) 2005-09-09

Similar Documents

Publication Publication Date Title
BRPI0508082A8 (pt) Anticorpo monoclonal de tenascina antihumano
RS54046B1 (en) ANTI-MIOSTATIN ANTITELA
DK1198250T3 (da) FC-fusionsproteiner til forstærkning af protein- og peptidantigeners immunogenicitet
PE20040554A1 (es) Vacunas que comprenden proteinas de fusion
CY1106594T1 (el) Αντισωματα εναντι ανθρωπινης il-12
TR200202799T3 (tr) AB peptidini sekanslayan insanlaştırılmış antikorlar
HRP20090517T1 (en) Interleukin-10 antibodies
PE20130643A1 (es) Conjugados de anticuerpos multifuncionales
CO6300960A2 (es) Anticuerpos humanos enlazantes de mesotelina y usos de los mismos
CR8231A (es) Anticuerpos rg1 y uso de los mismos
RS54111B1 (en) ANTI-ALPHA 2 INTEGRIN ANTIBODIES AND THEIR USES
EA200300464A1 (ru) ГУМАНИЗИРОВАННОЕ АНТИТЕЛО ПРОТИВ РЕЦЕПТОРА ЛИМФОТОКСИНА-β (ВАРИАНТЫ), КОМПОЗИЦИЯ, СПОСОБ ЛЕЧЕНИЯ ИЛИ СНИЖЕНИЯ РИСКА РАЗВИТИЯ, ТЯЖЕСТИ ИЛИ ПОСЛЕДСТВИЙ НЕОПЛАЗИИ У ЧЕЛОВЕКА, ВЫДЕЛЕННАЯ НУКЛЕИНОВАЯ КИСЛОТА (ВАРИАНТЫ), КЛЕТКА КЛЕТОЧНОЙ ЛИНИИ
CY1107447T1 (el) Ετερολογη εκφραση πρωτεϊνων των neisseria
ATE263189T1 (de) Antikörper gegen menschliches prostatspezifisches drüsenkallikrein
AR038700A1 (es) Anticuerpos monoclonales anti-tenascina humana
DE60043784D1 (de) Serpentinetransmembranrezeptoren exprimiert in menschlichem prostatakrebs und ihre verwendungen
DE69932812D1 (de) Epitope in der viralen hüllproteine und spezifische antikörper gegen diese epitope: verwendung für die detektion von hcv viralantigene im empfängergewebe
DE602006013428D1 (de) Chimaere rekombinante antigene von toxoplasma gondii
EP3636667A3 (en) Immunoregulatory structures from normally occurring proteins
ITRM20020049A1 (it) Frammenti fab di anticorpi monoclonali umani diretti contro la glicoproteina e2 di hcv e dotati di potere neutralizzante in vitro.
EP2261253A3 (en) Antibodies directed to Clostridium difficile
RS51406B (sr) Monoklonska antitela na humani ldl receptor, njihova produkcija i korišćenje
BR0015872A (pt) Agentes antitrombóticos
ATE435034T1 (de) Expression und charakterisierung eines hiv-1 hüllproteins, das mit einer breitreaktiven neutralisierenden antikörperantwort assoziiert ist.
WO2006131953A3 (en) Antibodies directed against the myelin basic protein recognising an epitope of cd64 and their use as immunosuppressants

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: TECNOGEN S.P.A. (IT)

Free format text: ALTERADO DE: TECNOGEN S.C.P.A.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25A Requested transfer of rights approved

Owner name: ALFASIGMA S.P.A. (IT)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 15A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2553 DE 10/12/2019.